Table 12.

China.

(A)			12/23/2019–03/18/2020*	03/20–07/22/2020
Position	Location	Mutation	Count	Count	Incidence
241nt	5´UTR	CG → TG	0/98	23/33	Prevalent
		noneffective
3,037nt	nsp3	CT → TT	2/99	23/33	Prevalent
		noneffective
8,782nt	nsp4	CC → TC	29/99	0/33	DE,ES,IN,US
		noneffective
14,408nt	RNA‐dependent RNA polymerase	CT → TT	2/99	19/33	Prevalent
		CCT (Proline) → CTT (Leucine)
23,403nt	Spike glycoprotein	AT → GT	2/99	22/33	Prevalent
		GAT (Aspartic Acid) → GGT (Glycine)
28,144nt	ORF8 protein	TA → CA	29/99	0/33	DE,ES,IN,US
		TTA (Leucine) → TCA (Serine)
28,881nt	Nucleocapsid phosphoprotein	GGG → AAC	2/99	11/33	Prevalent
		AGGGGA (Arginine Glycine) → AAACGA (Lysine Arginine)

(B)			01/19/2020–01/20/2021
Position	Location	Mutation	Total Count	Percentage
4nt	5´UTR	A → G	15	2.49
241nt		C → T	68	11.28
1,397nt	nsp2	G → A	18	2.99
2,392nt		T → C	13	2.16
3,037nt	nsp3	C → T	65	10.78
6,354nt		C → T	14	2.32
7,075nt		T → C	14	2.32
8,022nt		T → G	15	2.49
8,782nt	nsp4	C → T	191	31.67
10,747nt	3C‐like proteinase	C → T	14	2.32
11,083nt	nsp6	G → T	40	6.63
11,794nt		A → G	14	2.32
14,408nt	RNA‐dependent RNA polymerase	C → T	55	9.12
15,324nt		C → T	13	2.16
15,342nt		C → T	14	2.32
15,360nt		C → T	14	2.32
15,666nt		G → A	14	2.32
16,733nt	Helicase	C → T	14	2.32
17,373nt		C → T	26	4.31
18,060nt	3'‐to‐5' exonuclease	C → T	16	2.65
21,707nt	spike glycoprotein	C → T	24	3.98
21,727nt		C → T	14	2.32
22,020nt		T → C	16	2.65
23,403nt		A → G	67	11.11
25,416nt	ORF3a	C → T	14	2.32
26,144nt		G → T	39	6.47
27,213nt	ORF6	C → T	15	2.49
28,144nt	ORF8	T → C	212	35.16
28,688nt	Nucleocapsid phosphoprotein	T → C	13	2.16
28,854nt		C → T	14	2.32
28,881nt		G → A	33	5.47
28,882nt		G → A	31	5.14
28,883nt		G → C	31	5.14
29,095nt		C → T	31	5.14
29,742nt	3´UTR	G → T	19	3.15
29,835nt		C → T	14	2.32

The general design of these Tables follows the outline described in detail in the legend to Table 5 (United States). The number of sequences investigated for SARS‐CoV‐2 mutations is detailed in Tables for individual countries.